Post by PressRelease on May 08, 2023 9:00am
New Press Release - ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease
Comment by
G1945V on May 08, 2023 9:09am
"With the IND clearance for PMN310, the Company plans to initiate a Phase 1a clinical trial designed to evaluate the pharmacokinetics, safety and tolerability of a range of PMN310 doses in healthy adult volunteers." But WHEN! G1945V
Comment by
M101 on May 08, 2023 10:35am
"When?" Exactly, nothing says wait for the other shoe to drop (financing) quite like not hearing the other shoe drop (when).
Comment by
G1945V on May 08, 2023 2:21pm
An offering better be at a level of a lot more than $30M. And the Boston Group owning a 50%+ of ProMis. I can't see that with only putting in $10M. And you wouldn't what them owning a majority interest in the stock. I'm also in the conjecture territory. :) G1945V